The proteases BACE1 and BACE2 are involved in Alzheimer’s Disease (AD), myelination, and pancreatic ß-cell function. New substrates and phenotypes are being identified in mice and cells lacking BACE1 and/or BACE2, pointing to numerous potential (patho)physiological functions of both proteases. Additionally, BACE1 is currently one of the most promising drug targets against AD and several BACE1 inhibitors are tested in clinical trials for AD.
This meeting is the first one focusing exclusively on BACE proteases. It will bring together the internationally leading BACE researchers from both academia and industry to discuss the newest results on function and regulation of BACE proteases as well as chances and challenges for BACE protease-directed therapies.